World Obesity Day - Addressing the Obesity Challenge through Innovation
Obesity is a chronic disease with increasing prevalence and related comorbidities, making it a significant global concern. Overweight and obesity are major lifestyle-related illnesses that lead to various health issues, including cancers, diabetes, metabolic syndrome, and cardiovascular diseases. These comorbidities—such as type 2 diabetes, hypertension, respiratory dysfunction, arthritis, and depression—negatively affect health, increasing morbidity and mortality. The WHO projects that by 2030, 30% of global deaths will be linked to lifestyle diseases, which can be mitigated through effective risk factor identification and policy interventions. Therefore, early detection and diagnosis of obesity are essential.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) enhance glucose-dependent insulin release, lower glucagon secretion, and slow gastric emptying, leading to their successful use in treating type 2 diabetes. These agents also reduce food intake and promote weight loss, making them a focus for obesity treatment. GLP-1 agonists have demonstrated weight loss efficacy in preclinical and clinical trials.
Medicilon engages closely with clients in formulating integrated GLP-1 research plans, leveraging its extensive experience to deliver high-quality experimental designs and results. The company offers GLP-1 drug discovery, CMC research, pharmacodynamics research, PK studies, safety evaluations, and other related services. By the end of 2024, Medicilon has supported clinical approval for 11 GLP-1 drugs and is advancing multiple GLP-1 projects.
Medicilon Obesity and Diabetes Models——
Medicilon Assisted Projects——
Semaglutide (ZT001) Injection
On September 30, 2022, Beijing Peptide received CDE acceptance for their Semaglutide (ZT001) injection, an antidiabetic and anti-obesity medication for long-term weight management. As a partner of Bejing Peptide, Medicilon provided comprehensive preclinical research services for Semaglutide (ZT001) Injection.
MDR-001
On December 26, 2022, MindRank announced FDA clearance for MDR-001's IND application. MDR-001 is a novel, orally bioavailable small-molecule GLP-1R agonist developed using MindRank's AI platform, Molecule Pro?. Comprehensive preclinical studies show that MDR-001 has excellent potency, selectivity, and favorable ADME properties, along with promising pharmacokinetics and tolerability. Its superior preclinical efficacy and safety profile suggest it has best-in-class potential for treating obesity and type 2 diabetes, addressing significant medical needs. As MindRank's partner, Medicilon provided API process development and preparation R&D services for MDR-001.
Contact Us